TapImmune (NASDAQ: MRKR) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare TapImmune to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.
This is a summary of current recommendations and price targets for TapImmune and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceutical preparations” companies have a potential upside of 59.97%. Given TapImmune’s rivals stronger consensus rating and higher probable upside, analysts clearly believe TapImmune has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
11.1% of TapImmune shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.3% of TapImmune shares are held by company insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares TapImmune and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TapImmune Competitors||$2.03 billion||$140.19 million||-2.04|
TapImmune’s rivals have higher revenue and earnings than TapImmune. TapImmune is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares TapImmune and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
TapImmune has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500. Comparatively, TapImmune’s rivals have a beta of 1.17, suggesting that their average share price is 17% more volatile than the S&P 500.
TapImmune rivals beat TapImmune on 12 of the 13 factors compared.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.